• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

Tuesday 09/25/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

AIT Therapeutics

  • 6:04 PM

    Mycobacterium Abscessus Load Reduced by 65% NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) — AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced positive data at Day 81, the end of its NO-NTM Abscessus clinical trial.  The Company previously announced positive preliminary data through Day 51. “We continue to be delighted with the data from this trial.  With just 21

    Read more
  • 6:50 AM

    NEW YORK, AITB, (GLOBE NEWSWIRE) — AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced publication of its Phase 2, double-blind, randomized controlled trial for treatment of infants with moderately severe bronchiolitis.  The article, entitled Nitric Oxide Inhalations in Bronchiolitis: A Pilot, Randomized, Double-Blinded, Controlled Trial was published in the December 2017 issue of the peer-reviewed Pediatric Pulmonology journal. “We are pleased to see

    Read more
  • 12:08 PM

    No Serious Adverse Events Related to Treatment with Nitric Oxide Reported Compelling Preliminary Data on Key Secondary Endpoint of 6-Minute Walk NEW YORK, Nov. 27, 2017, AITB, (GLOBE NEWSWIRE) — AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that preliminary results from its NO-NTM Phase 2 study in Nontuberculous Mycobacteria (NTM) targeting patients suffering from Mycobacterium Abscessus Complex (MABSC)

    Read more
  • 11:19 AM

    NEW YORK, AITB,(GLOBE NEWSWIRE) —  AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced financial results for the three- and nine-months ended September 30, 2017. Operational Highlights include: On October 23, 2017, the last patient completed treatment in our Phase 2 NO-NTM abscessus trial for the treatment of Nontuberculous Mycobacteria (NTM) abscessus lung disease.  The Company expects to

    Read more
  • 4:23 PM

    ALLENTOWN, PA, Jan 27, 2015 (Marketwired via COMTEX) — Ambassador Financial Group, Inc. today announced the successful completion of a $5.1 million private placement issuance of common stock for Carroll Bancorp, Inc. (OTCQB: CROL), headquartered in Sykesville, Maryland in which it served as the exclusive placement agent. The offering of common stock at $16.50 per share was closed on January 23, 2014. The purchasers of stock in the private placement reflected a mix of new local individual investors, existing shareholders,

    Read more
Public Wire Banner